{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:04:20Z","timestamp":1788206660793,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008990","name":"Universit\u00e9 de Lorraine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000190","name":"University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006521","name":"School of Medicine, Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015544","name":"King's College Hospital Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jacc.2026.01.089","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:30:12Z","timestamp":1776781812000},"page":"1986-2005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiovascular Trials in Hemodialysis"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-2567","authenticated-orcid":false,"given":"Arsalan","family":"Hamid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Lipardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Borentain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alar","family":"Irs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":false,"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain C.","family":"Macdougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Tricoci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7599-0534","authenticated-orcid":false,"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.01.089_bib3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s11255-010-9857-x","article-title":"Cardiovascular disease in end-stage renal disease: the challenge of assessing and managing cardiac disease in dialysis patients","volume":"42","author":"Miller","year":"2010","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.jacc.2026.01.089_bib4","first-page":"S16","article-title":"Epidemiology of cardiovascular disease in chronic renal disease","volume":"9","author":"Foley","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.01.089_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.7624","article-title":"Trends in mortality due to myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis","volume":"5","author":"Ocak","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.01.089_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1525-139X.2002.00083.x","article-title":"Inflammation in end-stage renal disease: sources, consequences, and therapy","volume":"15","author":"Stenvinkel","year":"2002","journal-title":"Semin Dial"},{"key":"10.1016\/j.jacc.2026.01.089_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000327232","article-title":"Metabolic derangements seen in chronic kidney disease and end-stage renal disease patients","volume":"171","author":"Gupta","year":"2011","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.jacc.2026.01.089_bib8","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.2215\/CJN.05150418","article-title":"Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens","volume":"13","author":"Roberts","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.01.089_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0427","article-title":"Representation of patients with chronic kidney disease in clinical trials of cardiovascular disease medications: a systematic review","volume":"7","author":"Colombijn","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.01.089_bib10","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib11","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ejhf.2857","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Preserved trial","volume":"25","author":"Sharma","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.01.089_bib12","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib13","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib14","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/eurheartj\/ehx209","article-title":"Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints","volume":"40","author":"Rossignol","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.01.089_bib16","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/cts.13061","article-title":"Design and conduct considerations for studies in patients with impaired renal function","volume":"14","author":"Ravenstijn","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jacc.2026.01.089_bib17","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s11255-023-03516-1","article-title":"Multimorbidity prevalence and patterns in chronic kidney disease: findings from an observational multicentre UK cohort study","volume":"55","author":"Hawthorne","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.jacc.2026.01.089_bib18","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib20","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.01.089_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.03.023","article-title":"Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial","volume":"62","author":"Biagio","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2026.01.089_bib22","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2026.01.089_bib23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib24","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(25)01198-5","article-title":"Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial","volume":"406","author":"Michael","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.01.089_bib25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(25)01194-8","article-title":"Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis","volume":"406","author":"Patrick","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.01.089_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2023.1198560","article-title":"Pathophysiological concepts and screening of cardiovascular disease in dialysis patients","volume":"3","author":"Echefu","year":"2023","journal-title":"Front Nephrol"},{"key":"10.1016\/j.jacc.2026.01.089_bib27","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","article-title":"Chronic kidney disease and coronary artery disease: JACC state of the art review","volume":"74","author":"Sarnak","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.01.089_bib28","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2026.01.089_bib29","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/CIRCULATIONAHA.119.044195","article-title":"Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis","volume":"141","author":"Raggi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.01.089_bib30","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib31","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"95","author":"Andrew","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2026.01.089_bib32","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Gennaro","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.01.089_bib33","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure: a double-blind, placebo-controlled trial","volume":"56","author":"Gennaro","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.01.089_bib34","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1161\/CIRCULATIONAHA.117.027338","article-title":"Cardiovascular outcome trials in patients with advanced kidney disease","volume":"135","author":"Zannad","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.01.089_bib35","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.01.089_bib36","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ehf2.14268","article-title":"Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure","volume":"10","author":"Tardif","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2026.01.089_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ahj.2016.01.010","article-title":"The atrial fibrillation conundrum in dialysis patients","volume":"174","author":"de Vriese","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2026.01.089_bib38","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/rth2.12250","article-title":"Atrial fibrillation in patients with end-stage renal disease on hemodialysis: magnitude of the problem and new approach to oral anticoagulation","volume":"3","author":"K\u00f6nigsbr\u00fcgge","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.01.089_bib39","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.01.089_bib40","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.01.089_bib41","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"de Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.01.089_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jacasi.2024.11.014","article-title":"Left atrial appendage occlusion in patients receiving hemodialysis","volume":"5","author":"Mills","year":"2025","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacc.2026.01.089_bib43","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/ndt\/gfaa044","article-title":"Recruitment and retention in clinical trials in chronic kidney disease: report from national workshops with patients, caregivers and health professionals","volume":"35","author":"Natale","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2026.01.089_bib44","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib45","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1525-139X.2011.00912.x","article-title":"How should clinicians interpret cardiac troponin values in patients with ESRD?","volume":"24","author":"Jain","year":"2011","journal-title":"Semin Dial"},{"key":"10.1016\/j.jacc.2026.01.089_bib46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/ajkd.2001.25198","article-title":"Residual renal function and mortality risk in hemodialysis patients","volume":"38","author":"Shemin","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2026.01.089_bib47","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.xkme.2021.08.001","article-title":"Trends in adaptive design methods in dialysis clinical trials: a systematic review","volume":"3","author":"Judge","year":"2021","journal-title":"Kidney Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib48","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/biostatistics\/kxt010","article-title":"Adaptive enrichment designs for clinical trials","volume":"14","author":"Simon","year":"2013","journal-title":"Biostatistics"},{"key":"10.1016\/j.jacc.2026.01.089_bib49","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa1915925","article-title":"Management of coronary disease in patients with advanced kidney disease","volume":"382","author":"Bangalore","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib50","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","article-title":"Initial invasive or conservative strategy for stable coronary disease","volume":"382","author":"Maron","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib51","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/ndt\/gft355","article-title":"When do we need competing risks methods for survival analysis in nephrology?","volume":"28","author":"Noordzij","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2026.01.089_bib52","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.kint.2023.02.033","article-title":"Defining myocardial infarction in trials of people receiving hemodialysis: consensus report from the SONG-HD MI Expert Working group","volume":"103","author":"O\u2019lone","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2026.01.089_bib53","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a Presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.01.089_bib54","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020053","article-title":"Cardio\/kidney composite endpoints: a post hoc analysis of the EMPA-REG Outcome trial","volume":"10","author":"Ferreira","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.01.089_bib55","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.ajkd.2015.01.022","article-title":"Dose-finding study of rivaroxaban in hemodialysis patients","volume":"66","author":"de Vriese","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2026.01.089_bib56","doi-asserted-by":"crossref","first-page":"e701","DOI":"10.1016\/S2214-109X(20)30541-6","article-title":"The role and challenges of cluster randomised trials for global health","volume":"9","author":"Dron","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jacc.2026.01.089_bib57","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib58","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib59","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.jcin.2021.06.028","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndrome in relation to estimated glomerular filtration rate","volume":"14","author":"W\u00f6hrle","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.01.089_bib60","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT Renal","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.01.089_bib61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib62","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1161\/CIRCULATIONAHA.120.051020","article-title":"Apixaban or vitamin K antagonists and aspirin or placebo according to kidney function in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention","volume":"143","author":"Hijazi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.01.089_bib63","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib64","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib65","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jacc.2026.01.089_bib66","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib67","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","article-title":"Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial","volume":"8","author":"Mc Causland","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.01.089_bib68","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib69","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.01.089_bib70","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.01.089_bib71","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib72","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2029980","article-title":"Cryoablation or drug therapy for initial treatment of atrial fibrillation","volume":"384","author":"Andrade","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib73","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib74","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib75","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000528763","article-title":"Pitavastatin Compared With Differential Intervention Trial by Standard Therapy on Cardiovascular Events in Patients with Dyslipidemia on Chronic Hemodialysis (DIALYSIS): a randomized controlled trial","volume":"52","author":"Hamada","year":"2023","journal-title":"Blood Purif"},{"key":"10.1016\/j.jacc.2026.01.089_bib76","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(22)01805-0","article-title":"Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial","volume":"400","author":"Amit","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.01.089_bib77","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1001\/jama.2021.4807","article-title":"Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: the LANDMARK Randomized clinical trial","volume":"325","author":"Ogata","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.01.089_bib78","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib79","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.01.089_bib80","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40620-021-01104-z","article-title":"Calcifediol supplementation in adults on hemodialysis: a randomized controlled trial","volume":"35","author":"Morrone","year":"2022","journal-title":"J Nephrol"},{"key":"10.1016\/j.jacc.2026.01.089_bib81","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12882-020-01793-x","article-title":"The effect of BCM guided dry weight assessment on short-term survival in Chinese hemodialysis patients: primary results of a randomized trial\u2014Body Composition Monitor (BOCOMO) study","volume":"21","author":"Liu","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jacc.2026.01.089_bib82","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000020202","article-title":"Impact of twice- or three-times-weekly maintenance hemodialysis on patient outcomes: a multicenter randomized trial","volume":"99","author":"Dai","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacc.2026.01.089_bib83","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1001\/jama.2018.17749","article-title":"Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism receiving maintenance hemodialysis: the J-DAVID randomized clinical trial","volume":"320","author":"Investigators","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.01.089_bib84","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.ajkd.2008.04.031","article-title":"Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial","volume":"52","author":"Hiromichi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2026.01.089_bib85","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1542-4758.2007.00171.x","article-title":"Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events","volume":"11","author":"Vianna","year":"2007","journal-title":"Hemodia Int"},{"key":"10.1016\/j.jacc.2026.01.089_bib86","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2026.01.089_bib87","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(00)02783-5","article-title":"Secondary Prevention With Antioxidants of Cardiovascular Disease in Endstage Renal Disease (SPACE): randomised placebo-controlled trial","volume":"356","author":"Boaz","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.01.089_bib88","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial","volume":"56","author":"Cice","year":"2010","journal-title":"J Am Coll Cardiol"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726055737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726055737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:36:15Z","timestamp":1781253375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726055737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":86,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0735109726055737"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.01.089","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Trials in Hemodialysis","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.01.089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}